多西紫杉醇联合DSOX方案治疗晚期胃癌的临床效果及预后危险因素分析  

Evaluation on the Clinical Curative Effect of Docetaxel Combined with DSOX Regimen on Advanced Gastric Cancer and Risk Factors of Prognosis

作　　者：陈露[1] 陈贡斌[1] 马亚丽 CHEN Lu;CHEN Gongbin;MA Yali(The First People's Hospital of Shangqiu,Shangqiu,476000)

机构地区：[1]河南省商丘市第一人民医院,476000

出　　处：《实用癌症杂志》2021年第4期644-648,共5页The Practical Journal of Cancer

摘　　要：目的探讨多西紫杉醇联合DSOX方案治疗晚期胃癌临床效果及预后危险因素。方法回顾性分析60例晚期胃癌患者临床资料,按照治疗方案的不同,将采用多西紫杉醇联合奥沙利铂及替吉奥(DSOX)方案治疗的患者35例纳入A组,将给予奥沙利铂、5-氟尿嘧啶和亚叶酸钙治疗的患者25例纳入B组,比较2组临床疗效与安全性,分析影响患者预后的因素。结果A组临床治疗有效率(48.57%)高于B组(20.00%),差异有统计学意义(P<0.05);2组血小板减少、白细胞减少、贫血、胃肠道反应、肾功能损害、肝功能损害、心功能损害、肺功能损害、皮肤反应不良反应发生情况比较,差异无统计学意义(P>0.05)。随访截止至2020年2月29日,A组与B组6个月生存率分别为:82.86%、72.00%,1年生存率分别为:45.71%、20.00%,2年生存率分别为:11.43%、8.00%,2组患者6个月、2年生存率比较,差异无统计学意义(P>0.05);A组1年生存率高于B组(P<0.05)。COX比例风险回归分析结果显示ECOG体力状态评分、病理类型、转移情况、完成化疗周期数是晚期胃癌患者预后的影响因素。结论多西紫杉醇联合DSOX方案治疗晚期胃癌是一个有效的、不良反应可耐受的方案,ECOG体力状态评分、病理类型、转移情况、完成化疗周期数是患者预后的影响因素。Objective To explore the clinical curative effect of docetaxel combined with DSOX regimen on advanced gastric cancer and risk factors of prognosis.Methods The clinical data of 60 patients with advanced gastric cancer were retrospectively analyzed.According to different treatment regimens,35 patients who were treated with docetaxel combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules(DSOX)regimen were included in group A,while the other 25 patients who were treated with oxaliplatin,5-fluorouracil and calcium leucovorin were included in group B.The clinical curative effect and safety were compared between the two groups.The influencing factors of prognosis were analyzed.Results The response rate of clinical treatment in group A was higher than that in group B(48.57%vs 20.00%)(P<0.05).There were no significant differences in side effects such as thrombocytopenia,leukopenia,anemia,gastrointestinal reactions,renal function damage,liver function damage,cardiac function damage,lung function damage and skin reactions between the 2 groups(P>0.05).The follow-up lasted till February 29,2020.The 6-month,1-year and 2-year survival rates in group A and B were(82.86%,72.00%),(45.71%,20.00%)and(11.43%,8.00%),respectively.There were no significant differences in 6-month and 2-year survival rates between the two groups(P>0.05).The 1-year survival rate in group A was higher than that in group B(P<0.05).The results of COX proportional hazards regression analysis showed that score of ECOG physical status,pathological type,metastasis and cycles number of completed chemotherapy were influencing factors of prognosis in patients with advanced gastric cancer.Conclusion Docetaxel combined with DSOX is an effective and tolerable regimen in the treatment of advanced gastric cancer.The score of ECOG physical status,pathological type,metastasis status and cycles number of completed chemotherapy are influencing factors of prognosis.

关 键 词：晚期胃癌 多西紫杉醇 奥沙利铂 替吉奥 预后 危险因素 

分 类 号：R735.2[医药卫生—肿瘤]